Immunotherapy with Alternaria alternata: Present and future;Inmunoterapia con Alternaria alternata: Presente y futuro

Allergologia et Immunopathologia

Volumn 35, Issue SUPPL. 1, 2007, Pages 31-35

  Martinez Canavate Burgos, A ^a   Valenzuela Soria, A ^b   Rojo Hernandez A ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b Hospital Santa Ana   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGIC ASTHMA; ALLERGIC DISEASE; CONFERENCE PAPER; DISEASE COURSE; HUMAN; IMMUNOTHERAPY; MUSHROOM; PREVENTION AND CONTROL;

EID: 34548503902     PISSN: 03010546     EISSN: 15781267     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. Alergológica. Factores epidemiológicos, clínicos y socioeconómicos de las enfermedades alérgicas en España. Sociedad Española de Alergología e Inmunología Clínica, Alergia e Inmunología Abelló, S.A. eds. Madrid, 1995.
2. D'Amato G, Chatzigeorgiou G, Corsico R, Gioulekas D, Jäger L, Jäger S, et al. Evaluation of the prevalence of skin prick test positivity to Alternaria and Cladosporium in patients with suspected respiratory allergy. EEACI Position Paper. Allergy. 1997;52:711-6.
3. Alergologica 2005. Factores epidemiológicos, clínicos y socioeconómicos de las enfermedades alérgicas en España en 2005. Sociedad Española de Alergología e Inmunología Clínica. Schering-Plough. Madrid: Ergraf, 2006.
4. Estudio Escape: estacionalidad y seguimiento de la calidad de vida en el asma pediátrica en España. Madrid: Ergon, 2005.
5. Salvaggio J, Aukrust L. Mould-induced asthma. J Allergy Clin Immunol. 1981;68:327-46.
6. Infante F, Alba F, Caño M, Castro A, Domínguez E, Méndez J, Vega A. A comparative study of the incidence of Alternaria conidia in the atmosphere of five Spanish cities. Pólen. 1999;10:5-13.
7. Downs SH, Mitakakis TZ, Marks GB, Car NG, Belousova EG, Leuppi JD, et al. Clinical importance of Alternariaexposure in children. Am J Respir Crit Care Med. 2001;164:455-9.
8. Plaza V, Serrano J, Picado C, Cosano J, Ancochea J, De Diego A, et al; Grupo de Investigadores del Estudio Multicéntrico del Asma de Riesgo Vital. Características clínicas de las crisis de asma de riesgo vital en los pacientes sensibilizados a Alternaria alternata. Med Clin (Barc). 2003;121:721-4.
9. Garcia-Marcos L, Quiros AB, Hernandez GG, Guillen-Grima F, Diaz CG, Urena IC, et al. Stabilization of asthma prevalence among adolescents and increase among schoolchildren (ISAAC phases I and III) in Spain. Allergy. 2004;59:1301-7.
10. Aguinaga O, I, Arnedo PA, Bellido J, Guillen GF, Suarez Varela MM. The prevalence of asthma-related symptoms in 13-14-year-old children from 9 Spanish populations. The Spanish Group of the ISAAC Study (International Study of Asthma and Allergies in Childhood). Med Clin (Barc). 1999;112:171-5.
11. Zureik M, Neukirch C, Leynaert B, Liard R, et al.Sensitisation to airborne moulds and severity of asthma: Cross sectional study from European Community respiratory health survey/Commentary. London: British Medical Journal. (International edition). 2002;Tomo 325, No. 7361;41-415.
12. Des Roches A, Paradis L, Menardo JL Immunotherapy with a standardised Dermatophagoides pteronissynus extract VI. Specific immuntherapy prevents the onset of new sensitization in children. J Allergy Clin Immunol. 1997;99:450-3.
13. García A. Eficacia preventiva de la Inmuoterapia. Alergol e Inmunol Clin. 2000;15:64-6.
14. Kaad PH, Ostergaard PA. The hazard of mould hyposensitization in children with asthma. Clin Allergy. 1982;12:317-20.
15. Dreborg S, Agrell B, Foucard T, Kjellman M, Koivikko A, Nilsson S. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladospurium herbarum preparation. I. Clinical results. Allergy. 1986;41:131-40.
16. Martorell A, Sole A, Diez LV, Belenguer J, Sanz J, Torro MI, et al. Inmunoterapia en alergia a hongos. Rev Esp Alergol Inmunol Clin. 1986;1:188-92.
17. Malling HJ, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum. Allergy. 1986;41:507-19.
18. Horst M, Hejjaoui A, Horst V, Michel B, Bousquet J. Doubleblind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol. 1990;85:460-72.
19. Tabar Al, Lizaso MT, Garcia BE, Echechipía S, Olaguibel JM, Rodríguez A. Tolerance of immunotherapy with a standardized extract of Alternaria tenuis in patients with rhinitis and bronchial astma. J Investig AIlergo1 Clin Immunol. 2000;10:327-33.
20. Malling HJ, Weeke B. EAACI Immunotherapy Subcommittee. Position Paper Immunotherapy. Allergy. 1993;48:1-45.
21. Bousquet J, Lockey RF, Malling HG. WHO Position Paper. Allergen Immunotherapy: therapeutic vaccines for allergic diseases. Allergy. 1998;53:1-42.
22. Van Ree R. Indoor allergens. Relevance of major measurement and standardization. J Allergy Clin Immunol. 2007;119:270-7.
23. Aden E, Weber B, Bossert J, Teppke M, Franck E, Wahl R, Fiebig H, Cromwell O. Standardization of Alternaria alternata: Extraction and quantification of Alt a 1 using and mAB-based 2-site binding assay. J Allergy Clin Immunol 1999;104:128-35.
24. Lombardero M, Duffort O, Cortés C, Carreira J. Immunchemische und biologische characterisierung eines referenzextraktes aus Alternaria alternata .Allergologie. 1988;11:509.
25. Duffort O, Barber D, Polo F. Ensayo de cuantificación del alergeno mayoritario de Alternaria alternata. Alergol Inmunol Clin. 2002;17:162-8.
26. Asturias JA, Ibarrola I, Ferrer A, et al. Diagnosis of Alternaria alternata sensitization with natural and recombinant Alt a 1 allergens. J Allergy Clin Immunol. 2005;115:1210-7.
27. Cantani A, Businco E, Maglio A. Alternaria allergy: A three-year controlled study in children treated with immunotherapy. Allergol et Immunopathol. 1988;16:1-4.
28. Martinez-Cañavate A, Eseverri JL, Ródenas R, Tabar AI, Garde J, Torres J, Boné J, Pedemonte C. Evaluation of paediatric tolerance to an extract of Alternaria alternata under two treatment regimes. Amulticentre study. Allergol et Immunopathol. 2005;33:138-41.
29. Criado Molina, et al. Immunotherapy with an oral Alternaria extract in childhood asthma. Clinical safety and efficacy and effects on in vivo and in vitro parameters. Allergol et Immunopathol. 2002;30:319-30.
30. Rienzo V, Minelli M, Musarrat A, et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 year. Clin Exp. Allergy. 2005;35:560-4.
31. Benardis P, Agnoletto M, Puccenelli P, et al. Injective versus sublingual immunotherapy in Alternaria tennuis allergic patients. J Invest Allergol Clin Immunol. 1996:6:55-62.
32. Canonica GW, Baena-Cagnani CE, Bousquet J, et al. Recomendations for standarditazion of clinical trial with allergen specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) task force. Allergy. 2007;62:317-24.